Fatigue Measure | Change for Intervention Group (SD) | Change for Control Group (SD) | Between-group Effect Size | Between-group SRM |
---|---|---|---|---|
MBSR trial 1 (N = 35) | ||||
 FSI Total | 2.31 (1.26) | − 0.31 (1.09) | 1.51 | 2.22 |
 FSI Severity | 2.21 (1.41) | − 0.47 (1.20) | 1.80 | 2.04 |
 FSI-Interference | 2.31 (1.55) | − 0.18 (1.46) | 1.20 | 1.66 |
 FSI-3 | 2.74 (1.48) | − 0.61 (1.80) | 1.61 | 2.04 |
 SF-36 Vitality | − 18.28 (15.47) | − 1.29 (12.56) | − 0.93 | − 1.20 |
MBSR trial 2 (N = 71) | ||||
 FSI Total | 1.92 (1.86) | 1.58 (1.63) | 0.23 | 0.20 |
 FSI Severity | 1.43 (2.01) | 1.38 (1.92) | 0.04 | 0.03 |
 FSI-Interference | 2.22 (2.07) | 1.69 (1.94) | 0.29 | 0.26 |
 FSI-3 | 2.22 (2.05) | 1.70 (2.03) | 0.30 | 0.25 |
 SF-36 Vitality | − 21.51 (19.29) | − 10.00 (13.49) | − 0.78 | − 0.69 |
BEAT Cancer trial (N = 222) | ||||
 FSI Total | 0.55 (1.49) | − 0.02 (1.53) | 0.31 | 0.38 |
 FSI Severity | 0.49 (1.81) | 0.05 (1.63) | 0.23 | 0.25 |
 FSI-Interference | 0.58 (1.59) | − 0.09 (1.75) | 0.33 | 0.40 |
 FSI-3 | 0.65 (1.80) | − 0.02 (1.84) | 0.30 | 0.37 |
 SF-36 Vitality | − 11.61 (18.44) | 0.21 (17.29) | − 0.58 | − 0.66 |